Yashashwi Pokharel to Treatment Outcome
This is a "connection" page, showing publications Yashashwi Pokharel has written about Treatment Outcome.
Connection Strength
0.432
-
Pokharel Y, Jones PG, Graham G, Collins T, Regensteiner JG, Murphy TP, Cohen D, Spertus JA, Smolderen K. Racial Heterogeneity in Treatment Effects in Peripheral Artery Disease: Insights From the CLEVER Trial (Claudication: Exercise Versus Endoluminal Revascularization). Circ Cardiovasc Qual Outcomes. 2018 04; 11(4):e004157.
Score: 0.094
-
Pokharel Y, Chinnakondepalli K, Vilain K, Wang K, Mark DB, Davies G, Blazing MA, Giugliano RP, Braunwald E, Cannon CP, Cohen DJ, Magnuson EA. Impact of Ezetimibe on the Rate of Cardiovascular-Related Hospitalizations and Associated Costs Among Patients With a Recent Acute Coronary Syndrome: Results From the IMPROVE-IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circ Cardiovasc Qual Outcomes. 2017 05; 10(5).
Score: 0.088
-
Pokharel Y, Wei J, Hira RS, Kalra A, Shore S, Kerkar PG, Kumar G, Risch S, Vicera V, Oetgen WJ, Deswal A, Turakhia MP, Glusenkamp N, Virani SS. Guideline-Directed Medication Use in Patients With Heart Failure With Reduced Ejection Fraction in India: American College of Cardiology's PINNACLE India Quality Improvement Program. Clin Cardiol. 2016 Mar; 39(3):145-9.
Score: 0.081
-
Bhardwaj B, Spertus JA, Kennedy KF, Jones WS, Safley D, Tsai TT, Aronow HD, Vora AN, Pokharel Y, Kumar A, Attaran RR, Feldman DN, Armstrong E, Prasad A, Gray B, Salisbury AC. Bleeding Complications in Lower-Extremity Peripheral Vascular Interventions: Insights From the NCDR PVI Registry. JACC Cardiovasc Interv. 2019 06 24; 12(12):1140-1149.
Score: 0.025
-
Hira RS, Kataruka A, Akeroyd JM, Ramsey DJ, Pokharel Y, Gurm HS, Nasir K, Deswal A, Jneid H, Alam M, Ballantyne CM, Petersen LA, Virani SS. Association of Body Mass Index With Risk Factor Optimization and Guideline-Directed Medical Therapy in US Veterans With Cardiovascular Disease. Circ Cardiovasc Qual Outcomes. 2019 01; 12(1):e004817.
Score: 0.025
-
Khariton Y, Patel KK, Chan PS, Pokharel Y, Wang J, Spertus JA, Safley DM, Hiatt WR, Smolderen KG. Guideline-directed statin intensification in patients with new or worsening symptoms of peripheral artery disease. Clin Cardiol. 2018 Nov; 41(11):1414-1422.
Score: 0.024
-
Patel KK, Arnold SV, Chan PS, Tang Y, Pokharel Y, Jones PG, Spertus JA. Personalizing the Intensity of Blood Pressure Control: Modeling the Heterogeneity of Risks and Benefits From SPRINT (Systolic Blood Pressure Intervention Trial). Circ Cardiovasc Qual Outcomes. 2017 04; 10(4).
Score: 0.022
-
Qintar M, Chhatriwalla AK, Arnold SV, Tang F, Buchanan DM, Shafiq A, Pokharel Y, deBronkart D, Ashraf JM, Spertus JA. Beyond restenosis: Patients' preference for drug eluting or bare metal stents. Catheter Cardiovasc Interv. 2017 Sep 01; 90(3):357-363.
Score: 0.022
-
deGoma EM, Ahmad ZS, O'Brien EC, Kindt I, Shrader P, Newman CB, Pokharel Y, Baum SJ, Hemphill LC, Hudgins LC, Ahmed CD, Gidding SS, Duffy D, Neal W, Wilemon K, Roe MT, Rader DJ, Ballantyne CM, Linton MF, Duell PB, Shapiro MD, Moriarty PM, Knowles JW. Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry. Circ Cardiovasc Genet. 2016 Jun; 9(3):240-9.
Score: 0.020
-
Brodie BR, Pokharel Y, Garg A, Kissling G, Hansen C, Milks S, Cooper M, McAlhany C, Stuckey TD. Very late hazard with stenting versus balloon angioplasty for ST-elevation myocardial infarction: a 16-year single-center experience. J Interv Cardiol. 2014 Feb; 27(1):21-8.
Score: 0.017
-
Brodie B, Pokharel Y, Fleishman N, Bensimhon A, Kissling G, Hansen C, Milks S, Cooper M, McAlhany C, Stuckey T. Very late stent thrombosis after primary percutaneous coronary intervention with bare-metal and drug-eluting stents for ST-segment elevation myocardial infarction: a 15-year single-center experience. JACC Cardiovasc Interv. 2011 Jan; 4(1):30-8.
Score: 0.014